Vmbook Online ordering

Ignyta Inc

Ignyta, Inc. was a biotechnology company that focused on the development of precision oncology products. The company was founded in 2011 and was listed on the NASDAQ stock exchange under the ticker symbol "RXDX."

Ignyta's lead product candidate was entrectinib, a tyrosine kinase inhibitor that targets the ROS1 and ALK genes. The company also had a pipeline of other product candidates in various stages of development, including a CD73 inhibitor and a dual-targeting ovarian cancer therapy.

In January 2020, Ignyta was acquired by Roche Holding AG, a Swiss pharmaceutical company, for approximately $2.3 billion. As a result, Ignyta is no longer a publicly traded company and its stock is no longer listed on the NASDAQ exchange.